Furthermore, vemurafenib treatment increases the production of transforming growth factor β (TGF-β) by melanoma cells; TGF-β, in turn, causes CAFs’ activation and increased fibronectin production, involved in BRAF inhibitors’ resistance (Figure 3D) [94]. The gene discussed is TGFB1; the disease is melanoma.